Core Viewpoint - The announcement from Yuan Da Pharmaceutical Group indicates that their innovative traditional Chinese medicine GPN01360 for treating depression has successfully reached its clinical endpoint in a Phase II clinical trial in China [1] Group 1: Clinical Trial Details - The Phase II clinical trial was a randomized, double-blind, placebo-controlled, multi-center study involving 148 patients diagnosed with depression [1] - The treatment duration was 8 weeks, aimed at evaluating the efficacy and safety of GPN01360 compared to a placebo for treating depression characterized by liver qi stagnation and spleen deficiency [1] Group 2: Results and Efficacy - The results demonstrated that GPN01360 exhibited good safety and efficacy in treating depression [1] - The drug also showed significant improvement in symptoms associated with depression, including anxiety and insomnia [1]
远大医药：公司用于治疗抑郁症的中药1类创新药II期临床达到终点